Published in J Rheumatol on June 01, 1994
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis (2004) 2.82
Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther (2004) 2.58
Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis (2003) 2.33
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res (2001) 2.18
Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther (2004) 2.05
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther (2005) 2.03
Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther (2005) 2.02
In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol (2000) 1.77
Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum (2009) 1.56
Synovial tissue research: a state-of-the-art review. Nat Rev Rheumatol (2017) 1.38
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum (2010) 1.25
Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther (2006) 1.24
Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res (2000) 1.23
Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res (2002) 1.22
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther (2008) 1.16
Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest (1995) 1.15
Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies. Ann Rheum Dis (1995) 1.07
The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.07
Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci U S A (1995) 1.06
Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Ann Rheum Dis (1999) 1.06
Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther (2005) 1.03
Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int (2008) 1.03
Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther (2004) 0.98
Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance. Curr Rheumatol Rep (2011) 0.95
Serum immunoglobulins and the risk of rheumatoid arthritis. Ann Rheum Dis (1997) 0.95
Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families. Korean J Intern Med (2012) 0.88
Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Rheumatol Int (2010) 0.87
Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis? BMC Med (2014) 0.79
Antibodies against a novel nucleolar and cytoplasmic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma. Clin Exp Immunol (1998) 0.79
Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients. Rheumatol Int (2016) 0.78
Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy. Rheumatol Int (2011) 0.78
The challenge of early synovitis: multiple pathways to a common clinical syndrome. Arthritis Res (1999) 0.78
The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol (1995) 0.75
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Sera from patients with autoimmune disease recognize conformational determinants on the 60-kd Ro/SS-A protein. Arthritis Rheum (1991) 1.85
Primary septic arthritis in heroin users: early diagnosis by radioisotopic imaging and geographic variations in the causative agents. J Rheumatol (1987) 1.46
[Learning through problem-solving and the case of the fortuitoma]. Union Med Can (1992) 1.39
Antinuclear antibodies: the medium is the message. Clin Exp Rheumatol (2000) 1.38
Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest (1995) 1.15
Airways disease in rheumatoid arthritis patients. One element of a general exocrine dysfunction. Arthritis Rheum (1987) 1.11
A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. Genes Immun (2010) 1.03
Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kD protein is not a Ro protein. Clin Exp Immunol (1995) 1.01
In vitro studies on peripheral blood leucocytes in rheumatoid arthritis. Ann Rheum Dis (1974) 1.01
Interaction cloning and characterization of RoBPI, a novel protein binding to human Ro ribonucleoproteins. RNA (2000) 0.99
Airway disease in a subset of nonsmoking rheumatoid patients. Characterization of the disease and evidence for an autoimmune pathogenesis. Am J Med (1982) 0.92
Comparative esophageal and anorectal motility in scleroderma. Gastroenterology (1985) 0.92
Heterogeneity of human Ro ribonucleoproteins (RNPS): nuclear retention of Ro RNPS containing the human hY5 RNA in human and mouse cells. Clin Exp Immunol (2001) 0.91
Anti-Ro (SSA) antibodies: clinical significance and biological relevance. J Rheumatol (1996) 0.91
Eosinophilic synovitis: clinical observations on a newly recognized subset of patients with dermatographism. Arthritis Rheum (1986) 0.89
Rheumatoid arthritis associated autoimmune systems. J Rheumatol (1998) 0.89
Clinical significance of anti-Ro(SSA) antibody in rheumatoid arthritis. J Rheumatol (1988) 0.88
Rheumatoid arthritis: anti-Ro antibodies define a non-HLA-DR4 associated clinicoserological cluster. J Rheumatol (1993) 0.88
The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28 Varies Over Time and by Rheumatoid Factor Status in Early Inflammatory Arthritis (EIA). Results from the CATCH Cohort. Open Rheumatol J (2013) 0.87
Autoantibodies in human anti-Ro sera specifically recognize deproteinized hY5 Ro RNA. Clin Exp Immunol (1995) 0.85
Autoantigenic epitopes on hY5 Ro RNA are distinct from regions bound by the 60-kDa Ro and La proteins. J Immunol (1996) 0.84
IgG autoantibody response in HTLV-I-infected patients. Clin Immunol Immunopathol (1995) 0.83
Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis. Clin Ther (1996) 0.82
Is local antigen persistence responsible for the chronicity of the experimental immune arthritis of the rabbit. Experientia (1976) 0.82
Use of a hapten-carrier system in experimental immune arthritis in the rabbit. Arthritis Rheum (1977) 0.82
[Detection of antinuclear factors in rheumatic diseases]. Union Med Can (1974) 0.82
De novo synthesis of proteinase 3 by cytokine primed circulating human polymorphonuclear neutrophils and mononuclear cells. J Rheumatol (2000) 0.80
[Antineutrophil cytoplasmic antibodies in human pathologies]. Union Med Can (1993) 0.80
Expression of prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 in human osteoblasts. Biochem Biophys Res Commun (1994) 0.80
Identification of ribonucleoprotein (RNP)-specific protein interactions using a yeast RNP interaction trap assay (RITA). Biotechniques (1999) 0.80
Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids (1997) 0.80
Abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondylarthropathies without clinical evidence of inflammatory bowel disease. Eur J Nucl Med (1996) 0.79
[Diagnosis of gout: problems caused by crystallization "in vitro" of sodium urate]. Union Med Can (1979) 0.78
Finding a valid model for antineutrophil cytoplasmic antibody-related vasculitis. Arthritis Rheum (1997) 0.77
Chronic modulation of the autoimmune response following parvovirus B19 infection. J Rheumatol (1994) 0.76
RNA-labelled Ro and La ribonucleoprotein complexes reassembled in vitro; characterization by gel shift analysis. Clin Exp Immunol (1996) 0.76
snRNPs and scRNPs as autoantigens: clues to the etiology of the connective tissue diseases. Clin Rheumatol (1990) 0.76
Detection of anti-neutrophil cytoplasmic antibodies by immunoprecipitation. Clin Invest Med (1995) 0.76
Efficacy and tolerability of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis: a double-blind comparison with standard naproxen followed by an open-label trial. Curr Med Res Opin (1992) 0.75
Cross-reactivity of an anti-proteinase 3 antibody to elastase. Autoimmunity (1994) 0.75
Cross-reactivity of an anti-proteinase 3 antibody to elastase. Autoimmunity (1993) 0.75
On the origin of surface proteinase 3 of nonmyeloid cells: evidence favoring an exogenous source. Clin Immunol (2000) 0.75
[Clinical ethics and observations on death]. Union Med Can (1993) 0.75
Clinical and serological identification of 2 forms of complete heart block in children. J Rheumatol (1995) 0.75
Skin temperature of the knee: an unrecognized physical sign of inflammatory disease of the knee. Can Med Assoc J (1980) 0.75
[Polymyositis induced by D-penicillamine treatment of rheumatoid arthritis: apropos of 2 cases with antinuclear antibodies]. Union Med Can (1986) 0.75
Operationally defined single- and double-stranded DNA antigens in the Farr assay: diagnostic value. Eur J Clin Invest (1979) 0.75
Stiffness of the rib cage in a subset of rheumatoid patients. Lung (1988) 0.75
[Immunofluorescent deposits in normal rheumatoid skin]. Ann Immunol (Paris) (1977) 0.75
N-Acetyl-beta-hexosaminidase isoenzymes of amniotic fluid and maternal serum. Their relevance to prenatal diagnosis of the GM2 gangliosidoses. Clin Chim Acta (1977) 0.75
Elemental contamination in Vacutainer tubes used for blood collection. Int J Nucl Med Biol (1983) 0.75
[Textually transmitted diseases]. Union Med Can (1992) 0.75
Heterogeneity of ANCA sera showing atypical, peripheral and classical cytoplasmic immunofluorescence patterns. Adv Exp Med Biol (1993) 0.75
Southern blotting of long-term preserved DNA. Biotechniques (1997) 0.75
[Antinuclear antibodies and PHA response in rheumatoid arthritis]. Ann Immunol (Paris) (1977) 0.75
[New strategies of the Medical Research Council of Canada]. Union Med Can (1993) 0.75
[Serum zinc, copper and sulfhydryl groups in osteoarthritis and rheumatoid arthritis]. Union Med Can (1980) 0.75
Charcot-Leyden crystals in synovial fluid. Arthritis Rheum (1981) 0.75
Trace element contamination in blood-collecting devices. Int J Nucl Med Biol (1979) 0.75
[Rheumatoid polyarthritis: increase of M cells in blood mononuclear subpopulations]. Union Med Can (1976) 0.75
Open-label tolerability study of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis. Curr Med Res Opin (1992) 0.75
Immunological cross-reactivity of adenovirus structural proteins. J Virol Methods (1986) 0.75
Patient compliance with tenoxicam in family practice. Clin Ther (1994) 0.75
Malignancy prevalence in the first-degree relatives of persons with systemic lupus erythematous: a pilot study. Lupus (2006) 0.75
[From the molecule to the drug: innovation or distribution]. Union Med Can (1993) 0.75
[Genetics of the 3d type]. Union Med Can (1993) 0.75